Ischemic Brain Stroke and Mesenchymal Stem Cells: An Overview of Molecular Mechanisms and Therapeutic Potential

Yang Jingli, Wang Jing, and Yasmeen Saeed

1 Provincial Key Laboratory for Utilization and Conservation of Food and Medicinal Resources in Northern Guangdong, 288 University Ave, Zhejiang District, Shaoguan, Guangdong Province, China
2 Department of Neurology, The First Affiliated Hospital of Harbin Medical University, 157 Baojian Road Harbin, Heilongjiang, China 150081
3 Guangdong VitaLife Biotechnology Co., Ltd, No. 61 Xiannan Road, Nanhai District, Foshan, Guangdong, China 528200

Correspondence should be addressed to Yasmeen Saeed; yss_028@hotmail.com

Received 12 May 2021; Revised 12 October 2021; Accepted 4 May 2022; Published 25 May 2022

Academic Editor: Darius Widera

Copyright © 2022 Yang Jingli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ischemic brain injury is associated with a high rate of mortality and disability with no effective therapeutic strategy. Recently, a growing number of studies are focusing on mesenchymal stem cell-based therapies for neurodegenerative disorders. However, despite having the promising outcome of preclinical studies, the clinical application of stem cell therapy remained elusive due to little or no progress in clinical trials. The objective of this study was to provide a generalized critique for the role of mesenchymal stem cell therapy in ischemic stroke injury, its underlying mechanisms, and constraints on its preclinical and clinical applications. Thus, we attempted to present an overview of previously published reports to evaluate the progress and provide molecular basis of mesenchymal stem cells (MSCs) therapy and its application in preclinical and clinical settings, which could aid in designing an effective regenerative therapeutic strategy in the future.

1. Introduction

Ischemic stroke is attributed to a high disability rate with limited or no therapeutic options for functional recovery [1–3]. Intrinsically, ischemic stroke indicates the cascade of congesting events, i.e., thrombus formation and embolism, that ultimately decreases the local blood flow and cause oxygen deprivation in affected brain tissue. Besides, systemic hypoperfusion is another major factor in the occurrence of ischemic stroke [4].

According to the World Health Organization (WHO), ischemic stroke is the most ubiquitous subclass of stroke that affects almost 15 million people globally [5]. However, to date, available treatment preferences are largely precautionary in purview [6]. For instance, thrombolytic agents such as tissue plasminogen activator (tPA) exhibit limited or no physical recovery of patients suffering from stroke [6, 7]. Surgical interference can only aid in minimizing the risk of clot formation [8]. Therefore, an effective therapeutic strategy is required to prevent the onset of acute stroke and manage the chronic symptoms associated with neural ischemia, i.e., long-term neuroinflammation and localized necrosis [8, 9].

The recent decade has seen encouraging outcomes of mesenchymal stem cell therapy that holds promise to alleviate the burden of neurological disorders Moreover, initial study data of preclinical trials have also indicated the effectiveness, tolerance, and safety of MSC-based therapy [10]. Thus, MSCs were suggested as a promising candidate for ischemic brain injury patients [11]. However, effective dose and appropriate time of MSCs delivery are the main challenges in the clinical translation of stem cell therapy. Therefore, a carefully designed, future study plan is a prerequisite for randomized clinical application trials to estimate its functional clinical outcome [10].

Herein, we presented an overview of a previously published work regarding the role of stem cell therapy in ischemic stroke and its underlying molecular mechanisms. We
aim to provide the basis for establishing a future study to promote the clinical translation of stem cell therapy in ischemic brain diseases.

2. Significance of Therapeutic Application of MSCs in Ischemic Stroke

An insight into the biology of ischemic stroke indicates that a stream of molecular events initiates instantly after the onset of ischemic stroke, such as oxidative stress, increased level of intracellular calcium, excitotoxicity, and inflammation which results in apoptotic or necrotic neuronal cell death [12–14]. According to previously established studies [8], the ischemic avalanche followed by a stroke is comprised of three phases, i.e., (i) acute phase, (ii) the subacute phase, and (iii) the chronic phase (Figure 1). Further insights into its molecular events indicate that the acute phase takes almost 2 weeks to complete after the incidence of the injury [15]. The subacute or secondary phase continues its deleterious events up to 6 months after the onset of the lesion. The duration of the chronic phase could take months to years after stroke and may last for the rest of the patient’s life along with its neuro-damaging sequel [15].

Briefly, the biology of stroke indicates the role of inflammation in the parthenogenesis of stroke, which collectively points towards disruption of ionic balance, oxidative stress, and deregulation of signaling pathways that ultimately over-burden astrocytes and results in transient hyperglycolysis and calcium influx while accumulating a high concentration of lactate in the extracellular fluid [16]. For instance, a recent study by Sarah Martha’s article shows that molecules that control acid-base balance and electrolytes possess the potential to be effective therapeutic targets to preserve neurons in the ischemic brain [17].

Glial scar formation is another major hurdle in axon regeneration which ultimately exaggerates the inflammatory response and chronic pain [16]. Intriguingly, natural killer (NK) cells can develop infarction by secreting IFN-γ in T- and B-cell-independent mechanisms and stimulate local inflammation by secreting pro-inflammatory cytokines such as IFN-γ, IL-17a, TNF-α, IL-1β, IL-6, IL-12, and ROS after middle cerebral artery occlusion (MCAO) [16]. Besides, further studies have indicated the presence of activated T-cells, 60 days after the onset of the injury. Among T-cells, increased expression of CD4+ CD25+ FoxP3+ Treg cells and CD4+ CD28− T-cells are noticed in stroke patients [16].

It is also important to note that the recently available therapeutic strategy for acute ischemic stroke depends on reperfusion via endovascular or thrombolytic therapy [18]. However, limited therapeutic aperture for the administration of the thrombolytic agent TPA (<4.5 hours from symptom onset) and aggravation of blood-brain barrier (BBB) break down are drawbacks of these strategies [19–21]. Therefore, despite an increasing number of studies concerning the etiology, pathophysiology, and treatment of ischemic stroke [22–24], the range of therapeutic interventions has remained very limited [14, 25].

Nonetheless, stem cell therapeutic strategies have shown the potential to combat the deleterious effects of acute, sub-acute, and chronic phases of ischemic stroke [6]. Moreover, preclinical studies have demonstrated the safety of stem cell therapy against ischemic stroke by evaluating the possible therapeutic outcome [11]. Further studies have indicated that MSCs derived from umbilical cord lining (UC-MSCs) are profoundly immunolohomologically immature cells, and this property makes them a promising candidate for the treatment of stroke [26, 27]. For instance, UC-MSCs can potentially reduce the infarct size and ameliorate the functional recovery by elevating the expression of growth and neuroprotective factors such as brain-derived neurotrophic factor (BDNF) and vascular and endothelial growth factor (VEGF) [28–33]. Given these above-mentioned properties, MSCs have been designated as “Advanced Therapy Medicinal Products (ATMP)” according to the guidelines from the American Code of Federal Regulation of the Food and Drug Administration and the European Medicines Agency and the network of national agencies [34].

However, despite being regarded as potential therapeutic candidates for neurological disorders, the clinical application of mesenchymal stem cells has been challenged by poor migration of cells towards the injured site and low survival rate [35, 36]. Another constrain indicates that only a low percentage (<10%) of transplanted MSCs differentiate or express neuronal markers, i.e., NeuN and MAP-2 [32–35]. Given these limitations in therapeutic approaches, we attempted to investigate the role of mesenchymal stem cell therapy in neuroprotection and analyze it in light of previously reported studies.

3. Role of Stem Cell Therapy in Ischemic Stroke Recovery and Its Underlying Mechanisms

A growing number of studies have attempted to devise an effective therapeutic modality by considering the pathophysiology and underlying molecular mechanism of stroke [37]. Besides, recent studies have indicated the role of lncRNAs (long noncoding RNAs) in poststroke brain damage, thus suggesting a novel therapeutic target for stroke patients [38]. Stem cells and resident progenitors play an immense role in neuroplasticity after strokes, by the release of the growth factors and exosomes which accelerate post-stroke recovery [39]. Thus, stem cell therapy was suggested as a promising strategy for stroke and other neurological conditions. However, there is further comprehensive understanding of its molecular mechanism to unravel the intrinsic signaling pathways through which stem cells cooperate with the pathophysiology of stroke patients.

The efficiency of stem cell therapy is mainly attributed to the effective crossing of BBB to reach the target site in the brain [2]. Thus, based on previously reported studies, three hypotheses suggest the underlying neuroprotective mechanism of stem cell therapy. The primary hypothesis implies that MSCs reflect the immune system to inhibit the damaging effects of possible autoreactive responses and protect the central nervous system (CNS) [40]. Moreover, thrombosis and hypoxia trigger an intravascular inflammatory cascade, which further augments the innate immune response to cellular damage in the parenchyma and results in secondary
tissue injury [41], although the role of adaptive immunity in the pathogenesis of stroke and its long-term effects on the postischemic brain remained elusive. However, a persistent autoimmune response to brain antigens is a major damaging and long-lasting factor. Thus, it was suggested that immunity has long-term outcomes after stroke [41]. The second hypothesis emphasizes the secretion of neuroprotective factors by MSCs, which further trigger the innate repairing mechanisms of the central nervous system and negate the proceeding of neuronal tissue degeneration. For instance, stem cell treatment demonstrates apparent beneficial effects in preclinical stroke models by reducing infarct size and improving behavioral and histological deficits [42] by secreting the growth-promoting factors glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). For instance, accumulating evidence indicates that combined application of cell therapy with growth factors could significantly enhance the stimulation of endogenous neurogenesis, anti-inflammation, neuroprotection properties, and enhancement of stem cell survival rates that potentially contribute to functional recovery [42].

The third hypothesis indicates that transdifferentiation of MSCs into neural lineage can not be proved by in vivo evidence [45].

Besides, stem cells have been reported to promote nerve recovery either by the nerve repair strategy (injecting cells to the injury site) or by the immunomodulatory function. Stroke-relevant conditions such as deoxygenation and glucose deprivation can also be applied in combination with cocultured immune cells to study its impacts on its structural, functional, and expressional changes in the system [16]. Moreover, pharmacological targeting of AMP kinase activity, which is known to block microglia/macrophages M1 polarization, appears promising to improve stroke recovery in chronic kidney disease (CKD). Neurogenesis, which allows replacing damaged neurons, also favors stroke recovery [46].

Besides, immunomodulatory strategies determine the potent role of hypoxia in stem cell therapy via cell migration towards the target site [47], particularly regarding ischemic stroke. Concordantly, hypoxic preconditioning enhances the expression of angiogenic factors, peculiarly, VEGF, which further trigger the functional role of MSCs in repairing the infarcted myocardium [48, 49]. Further studies have suggested the association of the hypoxic microenvironment with cerebral ischemia, which further promotes the migration of UC-MSCs and incites their angiogenic properties via promoting their differentiation into vascular cells and enhancing the release of angiogenic factors. Besides, a low-oxygen environment elevates the expression of migration-related signaling factors and engraftment in UC-MSCs [50]. Accordingly, a preclinical study has suggested hypoxia as a prominent player in stimulating UC-MSCs to minimize neurological defects and promote angiogenesis in the brain of the rat ischemic stroke model. MSC-based therapy could potentially reduce the inflammatory response and neuronal

---

**Figure 1:** Graphical presentation of the various stages of cerebral ischemia stroke, i.e., acute phase, subacute phase, and chronic phase and their contributing factors.
cell apoptosis by modulating the immune system and impeding the secondary damage after ischemic stroke [14, 51, 52]. Accordingly, Figure 2 indicates the underlying molecular pathways through which MSCs counter the damaging effects of ischemic stroke in the brain (Figure 2). Another study has stated that the administration of stem cells during the subacute phase avert early cell death by curbing apoptosis, oxidative stress, mitochondrial impairment, and inflammation.

Furthermore, an elevated level of cytokines or growth factors (in case of ischemic brain injury) results in activation of survival signaling mechanisms in neurons such as MAPK/Erk1,2 pathways [53], while MSCs also aid in the upregulation of PI3-kinase resulting in the activation of Akt signaling and phosphorylation in neuronal cells, thus regulating neuronal survival or death [54]. Further investigations indicate that MSC-derived neurotrophic growth factors could be the main reason for stimulating the upregulation of PI3-K/Akt and MAPK survival signaling pathways in neurons. For instance, BDNF promotes the activation of the receptor tyrosine kinases (Trk), which results in the downstream stimulation of PI3-K/Akt and Erk1,2 signaling pathways and ultimately aid in the survival and differentiation of neurons [55].

Further insight into the underlying molecular mechanism has revealed that activation of the c-Jun N-terminal Kinase pathway (JNK) possesses a significant role in neuronal apoptosis during ischemic stroke [56]. Besides, JNK signaling is considered the preeminent factor regulating neuronal inflammation as focal cerebral ischemia and reperfusion (I/R) proceed [57, 58]. Inhibition of JNK activation could suppress glial cell inflammation and/or neuronal apoptosis, which results in neuroprotection [59]. Besides, the release of paracrine factors is another significant advantage of MSCs that not only promote the survival of astrocytes but also inhibit p38 MAPK and JNK by downregulating the expression of Glial Fibrillary Acidic Protein (GFAP) [60]. Accordingly, a study using the ischemic stroke mouse model has shown that intravenous intervention of bone marrow mesenchymal stem cells (BMSCs) inhibits the JNK signaling pathway and results in the reduction of neuronal cell apoptosis and modulation of the inflammatory response in the ischemic brain [14]. Moreover, BMSCs have been demonstrated to release a combination of numerous growth factors and cytokines that further stimulate the innate survival signaling pathways, including MAPK/ERK1/2 and the PI3K/Akt cascade [61]. Nonetheless, the neuroprotective effect of inhibiting the nuclear factor kappa-light-chain enhancer (NF-κB) of activated B cells has been reported to minimize the damaging effects of inflammation at the injured site [2, 62]. Collectively, the above-mentioned studies speculate that targeting inflammatory pathways via hindering the signaling cascade is the most commonly accepted potential strategy used by MSCs to minimize neurological damage (Figure 2).

The effectiveness and efficiency of stem cell therapy directly depend on the efficient crossing of the BBB by stem cells to sustain the probity of the BBB and to reach the targeted injured brain site [2]. Therefore, the regulation of BBB-specific mechanisms is the main factor in the success of MSC therapy. The evolutionary conserved canonical Wnt pathway (referred to as the Wnt/β-catenin pathway) [63] orchestrates BBB formation and maturation during ontogeny [21, 64]. Although the canonical Wnt pathway only has a nominal function in mature brain vasculature, it is vital for the maintenance of BBB integrity [65]. Activation of the canonical Wnt pathway establishes a clinically admissible approach to broaden the therapeutic efficiency.
by constricting the BBB breakdown and regulation of BBB-specific mechanisms [21]. Moreover, the canonical Wnt/β-catenin pathway stimulates the differentiation of MSCs into type II alveolar epithelial cells, which further huddles defiance against oxidative stress and boosts the MSC’s migration. Collectively, it was indicated that the Wnt/β-catenin pathway could be a crucial mechanism to augment the therapeutic effect of MSCs [8]. Yet, the precise mechanism (through which the Wnt/β-catenin pathway) enhancing the therapeutic effect of MSCs remains to elucidate[66].

Besides, the transcriptomic analysis has revealed the crucial of target genes, such as BCL2A1 and TPM2, in the pathogenic mechanism of ischemic stroke [64–67]. Nonetheless, future advancement in the creation of reliable human brain model systems in vitro holds the potential to improve high-throughput screening platforms and provide stroke researchers with a mechanism to screen large numbers of potential drug targets [16].

4. In Vivo Study Models of MSCs for Ischemic Stroke

Experimental data from in vitro ischemia models has shown that even short-term exposure of MSCs on neuronal cell survival at the injured site prominently decreases the detrimental effects of the inflammatory cascade [68]. Accordingly, intracerebral transplantation of MSCs in a rat model of stroke has been reported to induce neuronal activity by stimulating angiogenesis, reducing cell death, and immune response modulation [69, 70]. This property could be attributed to the release of paracrine factors by MSCs, peculiarly TGF-β, which reduce the CD68+ cell infiltration by inhibiting MCP-1 secretion [71, 72]. Intriguingly, another study reported a significant increase in the number of axons in a rat model of brain ischemic stroke, which continued even after one year of intra-arterial transplantation of MSCs [73]. Moreover, intra-arterially transplanted MSCs in the rat brain injured by stroke have been reported to reduce the IL-6 mRNA and IL-2 mRNA levels, thereby modulating the immune response [74]. In addition to mice or rat models for ischemic stroke injury, larger animals, i.e., dogs and swine, have also been tested for MSC transplantation to get more reliable data for clinical application. Accordingly, UC-MSCs have been reported to enhance the expression of biomarkers for astrocytes and neurons at the injured site after intra-arterial transplantation of MSCs [75]. Another study has indicated that MSC transplantation in the ischemic stroke model reduces the size of the damaged area and aid in faster recovery of motor function compared to the control animal model (which did not receive MSC injection) [76].

Moreover, a study using the neonatal mice model of brain damage provided evidence that intraperitoneal intervention of UC-MSCs in a neonatal model significantly reduced the activated microglia and reactive astrocytes in the white matter of neonatal mice brain [77]. Thus, it was suggested that transplanted MSCs play an immunosuppressive role in the neonatal mice model of ischemic brain injury [78]. It is also important to note that UC-MSCs exhibit therapeutic efficacy by modulating the inflammatory processes instead of cell replacement. Collectively, the safety and efficacy of intravenous intervention of UC-MSCs on a small animal model such as neonatal stroke mice, even with a higher dose (1 × 10^6) of UC-MSCs, were highlighted [47]. Accordingly, Table 1 summarizes some recent studies using animal models of ischemic stroke and mesenchymal stem cell therapy.

Intriguingly, a recent study has reported the use of companion animal model for ischemic stroke injury, since companion animal disease models could better represent the effectiveness and safety of stem cell therapy due to their similarity with human disease, particularly in terms of pathophysiological symptoms, therapeutic responses, gene associations, and biomarkers. Thus, a more effective model was provided for predicting the precise outcomes and risk associated with clinical trials in humans (for instance, the intravenous intervention of MSCs in the cat model for end-stage kidney disorder) [79]. Hence, companion animals could better portray the aftermath of regenerative medicine trials compared to rodent models [80]. Thus, we stated the conceptual advantages of large animal models in translational research, which makes them an attractive model for developing novel endovascular treatments for ischemic brain injury [81]. Nevertheless, large animal model experiments are often more complex than small animal studies. Therefore, training and pilot study plans are necessary for the optimization before the main trial, whereas the time and resource “loss” caused by such preliminary experiments can be atoned by increased reliability and decreased variability in the main trial [81].

Given the therapeutic efficiency of MSCs, we may suggest that MSC treatment could be a promising candidate for bringing a breakthrough in the field of regenerative therapy, especially for central nervous system injury and disease (which severely lack an effective therapeutic strategy) [70]. However, further clinical validation of these studies is required.

5. Preclinical and Clinical Trials of MSCs

A growing number of studies from preclinical research suggest stem cell therapy as a promising candidate to treat ischemic brain injury and to reduce its long-lasting effects [82], although the success in phase I clinical trials of stem cell therapy for stroke has significantly enhanced the confidence of the researcher and clinicians for clinical application of stem cell therapy [11]. However, further refinement is required concerning its clinical practicality and to confirm the efficacy and safety of these treatments [83, 84]. Besides, to ensure the solution of ethical, technical, and medical problems before clinical translation, the basic rules underpinning the use of MSCs in clinical trials for stroke patients have been established by the National Institutes of Health Consortium "Stem Cell Therapies as an Emerging Paradigm for Stroke (STEPS)" [68, 85]. In essence, according to STEPS, human trials could either include acute administration of stem cells to minimize the secondary risk of ischemic
| Sr# | Types of model | Source of stem cells | Time of administration | Dose | Delivery route | Efficacy | Important findings |
|-----|----------------|----------------------|------------------------|------|----------------|----------|-------------------|
| 1   | Rats underwent middle cerebral artery occlusion (MCAO) and reperfusion | Mesenchymal stem cells (MSCs) | 3-7 days after MCAO | $1 \times 10^6$ cells/200 μL PBS | Intravenous administration into the tail vein | Enhanced repair to ischemic stroke, through suppression to ischemia-induced microglial activation | This study observed a decreased expression of mincle, a damage-associated molecular pattern (DAMP) receptor, which induces the production of proinflammatory cytokines, suggestive of a potential mechanism in 3D MSC-mediated enhanced repair to ischemic stroke [109] These findings could shift cell therapy strategies for stroke from intravenous delivery of MSCs to their direct injection into lateral ventricles harboring the CP, which could enhance functional recovery [110] |
| 2   | Brain stroke model | Rat (r) MSCs | 1 hour after the ischemia/reperfusion | $10^6$ ION labeled MSCs in 10 μL saline | Injected into the right CC 1 h after the ischemia/reperfusion procedure | Crosstalk with the CP enhances MSC proliferation and migration in a transwell assay | These findings could shift cell therapy strategies for stroke from intravenous delivery of MSCs to their direct injection into lateral ventricles harboring the CP, which could enhance functional recovery [110] |
| 3   | Establishment of transient middle cerebral artery occlusion model | Human cranial bone-derived mesenchymal stem cells (hcMSCs) | 3 or 24 h after MCAO | 3 or 24 h after MCAO | The cells were administered intravenously through the tail vein | Suppresses the damage of residual nerve cells and leads to functional recovery | This is the first report demonstrating a functional recovery effect after ischemic stroke following hcMSC transplantation [111] hESC-MSC-CM remarkably attenuates neurological deficits as well as lesion volume in MCAO rats [112] |
| 4   | Middle cerebral artery occlusion (MCAO) | Conditioned medium (CM) derived from human embryonic MSC (hESC-MSC) | Either one time (1 h post MCAO) or three times (1, 24, and 48 h post MCAO) | 5 μL at a flow rate of 0.5 μL/min | Intracerebroventricular | Improved neurogenesis and angiogenesis to accelerate the recovery of cerebral ischemia insult | TrkB-MSCs promote the expression of BDNF and NT4, induce the differentiation of TrkB-MSCs, and improve motor function |
| 5   | Mouse model of transient focal cerebral ischemia | Tropomyosin receptor kinase B (TrkB) gene-transfected mesenchymal stem cells (TrkB-MSCs) | Five days after MCAO | $1 \times 10^6$/2 μL phosphate-buffered saline (PBS) | Injected at an infusion rate of 0.5 μL/min into the peri-infarct site: anteroposterior | The transplantation of neural stem cells within 24 hours after ischemia led to a reduction in the neural cells death | TrkB-MSCs improve motor function in the mouse model [113] |
| 6   | Intraluminal middle cerebral artery occlusion (MCAO) | Neural stem cells were isolated from the subventricular zone of the rat brain | 24 hours after local ischemia | $5 \times 10^5$ floating cells in 100 μL of PBS | External carotid artery (ECA) lumen | The transplantation of neural stem cells within 24 hours after ischemia led to a reduction in the neural cells death | Reduction in the neural cell death in the ischemic zone and the brain damage decreased significantly [114] |
| 7   | Ischemic stroke mice | Neural stem cells (NSCs) | 3×10^5 cells | i.v. injection | | The BDNF-NSC treatment | The present study investigates the ROS- |
injury, or it can be a late intervention during the chronic phase of the stroke to augment neuronal regeneration [11].

Moreover, further evidence accumulated from previous clinical trials has suggested the need to improve crucial factors, i.e., appropriate selection of suitable cells and route of administration to effectively translate preclinical results into effective clinical practice [86]. Herein, Table 1 presents a list of recent clinical trials of ischemic brain stroke using mesenchymal stem cell therapy from the ClinicalTrial.gov database (http://www.clinicaltrials.gov). The major limitation of these clinical trials is the small number of patients, which indicates small study effects (Table 2), especially in a single-arm study where the number of samples hardly approaches double figures [36]. However, it is also important to note that early-phase research often includes a smaller size sample; therefore, additional subgrouping seems impractical [83]. Thus, the requirement of a larger sample size for the accurate estimation of stem cell therapy effects was stated [36]. Yet, to date, no study has shown any promising results; therefore, a collaborative effort is a prerequisite to understanding the precise molecular mechanisms representing critical lab-to-clinic translational enabling factors that will lead towards safe and efficient stem cell therapy for the brain ischemic stroke [2].

The development of potency assays during preclinical animal testing is a cardinal aspect before translating cellular therapies into advanced stages of clinical trials. Besides, accurate recognition of safety and efficacy allows it to proceed to phase I/IIa clinical trials [87]. However, it is also important to mention that these clinical trials should first focus on safety confirmation, whereas efficacy endpoints should be next to safety [87].

Moreover, biomarkers with presumed mechanisms of action are also considered critical regulators for late-stage clinical trial approval. Additionally, it has also been recommended to use biomarkers to develop robust, specific, informative, and reproducible potency assays with the potential to describe a fundamental biological effect of the expected benefit [36, 87]. Since the inadequate quality of preclinical tests has been previously considered a major reason for the unsuccessful translation of experimental stroke therapies into the clinic [88, 89], therefore, it is necessary to evaluate and perform preclinical and clinical trials under Good Manufacturing Practice (GMP) before processing it to further clinical trial phases [87].

### 6. Limitations and Overcoming Challenges in Using MSCs for Ischemic Stroke

Notably, in addition to beneficial effects, MSC administration has exhibited some setbacks and side effects for the recipients. Therefore, characterizing the limitations of MSCs activity after their transplantation could aid in identifying a more voracious and comprehensive prospect and role of MSCs in the field of regenerative medicine. Accordingly, here, we highlight some crucial limiting factors of MSCs in the light of previous studies and discuss some aspects to overcome these challenges. Among these factors, the route of administration of stem cells, timing of stem cell delivery, and dose of cells are basic constraints in the clinical translation of stem cell therapy [83]. Although several studies have attempted to investigate the appropriate dose or route of administration of stem cells, yet it is difficult to predict any consequences [36]. Moreover, the correlation of some adverse events such as microocclusion to intra-arterial cell infusion has raised serious safety concerns [66, 88, 90]. Therefore, careful optimization of the intra-arterial infusion procedures should consider before efficacy studies [91, 92], while cell size and infusion velocity also indicate microocclusion after intra-arterial cell injection [91]. The fact remains that infusion velocity is also closely related to safe intraarterial administration. Therefore, before planning future preclinical and clinical efficacy studies, careful optimization of cell dose and infusion velocity should be considered on the basis type of stem cells to be delivered [88]. Collectively, it was suggested that appropriate time of MSC administration after the onset of stroke, the optimum dose of cells, and the adequate frequency of stem cell application with precise follow-up could enhance the chances of effective clinical translation of mesenchymal stem cell therapy.

The other concern is the translation of preclinical trials to clinical practice. Despite experimenting with several treatment strategies and various cell types in animal models, their clinical efficacy on stroke patients has not yet been confirmed [93]. The reason for inadequate clinical evidence can attribute to the significant differences in study design between preclinical and clinical trials [62, 94]. The difference in the therapeutic effect of preclinical studies could be due to heterogeneity in infarct size and recipient comorbidities. For instance, <90% of animals used in preclinical trials are reported healthy before stroke induction, whereas many
| Sr# | ClinicalTrials.gov identifier | Study type | Type of cell | Type of stroke | Patients demography | Delivery route | Dose safety & efficacy | Study objectives |
|-----|-------------------------------|------------|--------------|----------------|--------------------|---------------|------------------------|------------------|
| 1   | NCT01019733                  | Phase n/a interventional | Autologous hematopoietic (CD34+) cells | Hypoxic/ischemic brain injury | 18 participants of 1 year to 8 years (child) of all sexes | Intrathecal administration | 5 to 10 mL of stem cells will be infused intrathecally | An overall 4.7-month increase in developmental age according to the Battelle Developmental Inventory PM |
| 2   | NCT04590118                  | Phase randomized open-label | Allogeneic umbilical-cord mesenchymal stem cells | Ischemic stroke | 18 years or older clinical diagnosis of ischemic stroke for more than 6 months | Single intravenous infusion of it-hMSC for ischemic stroke patients | Single intravenous infusion of $0.5 \times 10^6$, $1 \times 10^6$, and $2 \times 10^6$ hMSC/kg | The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of a single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo-controlled trial |
| 3   | NCT03186456                  | Phase I/II interventional | Allogeneic umbilical-cord mesenchymal stem cells | Cerebral infarction | 18 years or older, diagnosis of more than 6 months exhibiting functional deficit | Intravenous infusion | Single intravenous infusion of $0.5 \times 10^6$, $1 \times 10^6$, and $2 \times 10^6$ it-hMSC/kg | A phase I/IIa study to evaluate the safety, tolerability, and preliminary efficacy of a single injection of it-hMSC in patients with ischemic stroke |
| 4   | NCT03176498                  | Phase I/phase I, nonrandomized | Allogeneic umbilical-cord mesenchymal stem cells | Cerebral infarction | 20 years to 75 years, proved cerebral infarction by CT or MRI. | Intravenous infusion | The experimental group received allogeneic umbilical cord mesenchymal stem cell and aspirin enteric-coated tablets, 0.1 g/d by mouth | The effects of human umbilical cord mesenchymal stem cell therapy on neurological function for cerebral infarction patients in convalescent period |
| 5   | NCT04097652                  | Phase I randomized | Human umbilical cord-derived mesenchymal stem cells (UMCI19-06) | Transient ischemic attack | 9 patients with 20 years to 80 years onset of ischemic stroke within 48 to 168 hours before the start of treatment | Intravenous infusion | Low does to a high dose of UMC19-06 with three months of time frame | The safety and tolerability after intravenous infusion of UMC19-06 in subjects with acute ischemic stroke |
| 6   | NCT04093336                  | Phase I/II nonrandomized | Human umbilical cord mesenchymal stem cells | Cerebral infarction/acute ischemic stroke | Patients aged 18–80 years with a clinical diagnosis of ischemic stroke for more than 6 months | Intravenous transplantation | Intravenous MSCs $2 \times 10^6$/kg as a single dose and standardized treatment of acute ischemic stroke | Effect of human umbilical cord mesenchymal stem cell (MSC) transplantation for prognosis of acute cerebral infarction patients |
| 7   | NCT01310114                  | Phase II randomized | Human placenta-derived cells (PDA001) | Acute ischemic stroke | Patients of all sexes with 18 years to 80 years of age | Intravenous infusion | $2 \times 10^6$ cells in 240 mL per infusion | A phase 2A, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety of intravenous infusion of human placenta-derived cells |
Table 2: Continued.

| Sr# | ClinicalTrials.gov identifier | Study type | Type of cell | Type of stroke | Patients demography | Delivery route | Dose safety & efficacy | Study objectives |
|-----|--------------------------------|------------|--------------|----------------|---------------------|----------------|------------------------|------------------|
| 8   | NCT01297413                    | Phase I/II, randomized open-label | Allogeneic adult mesenchymal bone-marrow stem cells | Ischemic stroke | 18 years and older with clinical diagnosis of ischemic stroke for longer than 6 months | Intravenous infusion | Intravenous one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells | (PDA001) for the treatment of adults following ischemic stroke A phase I/II, multicenter, open-label study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of allogeneic mesenchymal bone marrow cells to subjects with ischemic stroke |
| 9   | NCT02580019                    | Phase II randomized | Human umbilical cord mesenchymal stem cells | Ischemic stroke | 18 years to 70 years confirmed diagnosis of intracerebral ischemic stroke in three months by magnetic resonance imaging (MRI) | Intravenous infusion | A single dose of $2 \times 10^7$ hUC-MSC will be treated to patients | Cell therapy by intravenous injection of umbilical cord derived mesenchymal stem cells after stroke |
stroke patients suffered from comorbidities such as hypertension, diabetes, and heart disease. Furthermore, stroke patients often take medications such as antidiabetics to counter comorbidities, and these compounds may interact with injected cells [95, 96]. Besides, cell donors’ and recipients’ ages can influence cell treatment efficacy [97]. Therefore, efficient translation of preclinical study into a successful clinical trial requires the same time window, acute, subacute, or chronic; the same delivery route; the same cell dose (number of cells per kg/body surface area); the same cell immunogenicity; the same preparation procedure before transplantation (e.g., fresh vs. cryopreservation); the same target infarcts (e.g., hemispherical infarcts of middle cerebral artery territory only, with or without reperfusion); matched sex profile; matched age; the same comorbidity; and the same concomitant treatment [93]. Another constrain indicates that age and associated comorbidities such as hypertension and atherosclerosis could alter the vascular constitution and influence the clotting frequency [95]. Therefore, in the future, an optimal protocol of MSC transplantation with enhanced homing and reduced complications is required to be further established and facilitate its translation from bench to clinic [98].

Hence, future comprehensive studies are required to determine the factors, i.e., the optimum time required for isolation, proliferation, characterization of MSCs, and their ability to reach the target site [68, 75]. Besides, it is also crucial to confirm that the intervention of MSCs should not affect the medication or pathophysiology, or illness of patients, and these strategies should pave the way for the application of modified cells [75, 99].

7. Future Advancement

The successful outcome of preclinical studies encourages their clinical translation [75, 100]. Accordingly, several bioengineering approaches have assisted in improving the local administration of MSCs. For instance, engineered MSCs are an attractive resource for regenerative therapy due to their specific homing at the target site and their properties to operate with maximum efficiency regardless of the host environment. Besides, a recent study has indicated that identifying host factors that affect the function of MSCs can guide the development of improved MSC application by complementing the host priming strategy for a better therapeutic outcome [101]. However, the clinical application of these recommendations requires further evaluation at the laboratory level to achieve effective clinical trial outcome [101].

Intriguingly, a previous study has shown that multipotent adult progenitor cells administered in patients with acute ischemic stroke exhibited no side effects [102]. However, even after the 90 days of treatment with multipotent adult progenitor cells, no significant improvement in neurological outcomes was observed [102]. Besides, another study demonstrated that intra-arterially delivered autologous bone marrow-derived ALD-401 cells in patients with ischemic stroke did not cause any clinically adverse events in patients with subacute ischemic stroke. However, magnetic resonance imaging (MRI) exhibited a higher incidence of small lesions in the treatment group [103].

Hence, to date, ischemic stroke has no approved treatments to enhance the efficiency of recovery [103]. Besides, a combination of stem cell treatment with interventional procedures has proposed the application of synergistic effects to reinforce the effectiveness of stem cell therapy. Yet, very few good practical conceptions or in-depth studies support this evidence. Further, we will brief some combinational therapies that could be applied to achieve the best clinical outcome.

Among combinational therapies, “Drug-Cell Interaction” holds significant importance [87]. For instance, during clinical practice, patients receiving cell therapy also use medications to deal with stroke comorbidities and secondary prevention. Thus, it was suggested that cell therapy combined with pharmacological treatments enhances its therapeutic effects. However, due to the paracrine effects of stem cells, interactions between drugs and cells cannot be ignored [87]. Therefore, an efficient future perspective for the treatment of ischemic stroke is a prerequisite [87]. Recently, increasing integration of biomaterials has been observed for the efficient delivery of cells to minimize the shear stress caused by needle injections [104, 105] and to improve post-transplantation cell survival [106, 107]. For instance, scaffolds provide structural cues and biochemical signals to support transplanted cells inside the lesion cavity [106, 108]. Systematic optimization of a hydrogel improves the survival and differentiation of human neural stem cells implanted into the stroke-damaged brain [87]. However, scarce evidence indicates the role of combination therapy in functional recovery after ischemic stroke. Moreover, most studies combining biomaterials and cell transplantation are investigatory in nature rather than confirmative studies [87]. Thus suggesting that combinational cell therapies possess the potential to reopen the plasticity time window in chronic stroke, while neurorhabilitation could further aid in recovering the normal functioning of stroke patients [87].

Finally, it is also important to mention that the safety demonstration of multiple preclinical endpoints could be a valuable source upon clinical translation of cellular therapies for stroke treatment. Therefore, a stronger focus on safety rather than confirming efficacy in early preclinical research followed by early safety-oriented clinical research holds the potential to accelerate translational research without compromising the quality [87].

8. Conclusion

MSC therapy combined with novel integrative strategies presents an attractive therapeutic modality for treating ischemic stroke. However, due to unsatisfactory clinical outcomes and a lack of understanding about the molecular mechanism, these strategies could not receive approval for their application at the clinical level. Therefore, complete knowledge about molecular events and signaling modalities is required to enhance the efficacy and safety of stem cell therapy. Moreover, developing an efficient therapeutic strategy requires further understanding of the transdifferentiation of
transplanted stem cells, their immunomodulatory response, and the mechanism through stem release of growth factors. Nonetheless, cutting-edge technology adapted to high-throughput screening platforms can provide stroke researchers with a mechanism to screen large numbers of potential drug targets in the future. Hence, despite multiple challenges, clinical translation of preclinical studies along with novel therapeutics strategies could make a firm basis for the progression of regenerative medicine in the future.

Abbreviations

GFAP: Glial Fibrillary Acidic Protein
JNK: Pathway c-Jun N-terminal kinase pathway
p38: Protein 38
MAPK: Mitogen-Activated Protein Kinase
PI3K: Phosphatidylinositol-3-Kinase
Akt: Akt kinase or protein kinase B or PKB
ERK1/2: Extracellular signal-regulated kinases 1 and 2
rtPA: Recombinant tissue plasminogen activator
Wnt: Wnt/β-catenin signaling pathway
NeuN: Neuronal nuclear protein
MAP-2: Microtubule-associated protein-2
BMSCs: Bone marrow stem cells
UC-MSCs: Umbilical cord-derived mesenchymal stem cells
BBB: Blood-brain barrier
CAMs: Cell adhesion molecules.

Conflicts of Interest

All authors declare that there is no conflict of interest.

Authors’ Contributions

Jingli Yang and Jing Wang contributed equally to this work.

References

[1] J. Li, Q. Zhang, W. Wang, F. Lin, S. Wang, and J. Zhao, “Mesenchymal stem cell therapy for ischemic stroke: a look into treatment mechanism and therapeutic potential,” Journal of Neurology, vol. 268, no. 11, pp. 4095–4107, 2021.
[2] C. V. Borlongan, L. E. Glover, P. R. Sanberg, and D. C. Hess, “Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy,” Current Pharmaceutical Design, vol. 18, no. 25, pp. 3670–3676, 2012.
[3] T. Truelsen, L. H. Krarup, H. K. Iversen et al., “Causes of death data in the global burden of disease estimates for ischemic and hemorrhagic stroke,” Neuroepidemiology, vol. 45, no. 3, pp. 152–160, 2015.
[4] J. P. Broderick, T. Brott, T. Tomiick, R. Miller, and G. Huster, “Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage,” Journal of Neurosurgery, vol. 78, no. 2, pp. 188–191, 1993.
[5] A. S. Go, D. Mozaffarian, V. L. Roger et al., “Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association,” Circulation, vol. 127, no. 1, pp. 143–152, 2013.
[6] T. Dailey, C. Metcalf, Y. I. Mosley et al., “An update on translating stem cell therapy for stroke from bench to bedside,” Journal of Clinical Medicine, vol. 2, no. 4, pp. 220–241, 2013.
[7] Y. Zhang, G. Ying, C. Ren et al., “Administration of human platelet-rich plasma reduces infarction volume and improves motor function in adult rats with focal ischemic stroke,” Brain Research, vol. 1594, pp. 267–273, 2015.
[8] C. Stonesifer, S. Corey, S. Ghanekar, Z. Diamandis, S. A. Acosta, and C. V. Borlongan, “Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms,” Progress in Neurobiology, vol. 158, pp. 94–131, 2017.
[9] R. Jin, L. Liu, S. Zhang, A. Nanda, and G. Li, “Role of inflammation and its mediators in acute ischemic stroke," Translational Research, vol. 6, no. 5, pp. 834–851, 2013.
[10] M. Alessandrinii, O. Preynat-Seauve, K. De Bruin, and M. S. Pepper, “Stem cell therapy for neurological disorders,” South African Medical Journal, vol. 109, no. 8b, pp. 70–77, 2019.
[11] S. Zhang, B. B. Lachance, B. Moiz, and X. Jia, “Optimizing stem cell therapy after ischemic brain injury,” J Stroke, vol. 22, no. 3, pp. 286–305, 2020.
[12] F. C. Barone, “Ischemic stroke intervention requires mixed cellular protection of the penumbra,” Current Opinion in Investigational Drugs, vol. 10, no. 3, pp. 220–223, 2009.
[13] L. Lammerding, A. Slowik, S. Johann, C. Beyer, and A. Zenededel, “Poststroke Inflammassome expression and regulation in the Peri-infarct area by gonadal steroids after transient focal ischemia in the rat brain,” Neuroendocrinology, vol. 103, no. 5, pp. 460–475, 2016.
[14] Z. Vahidinia, A. Azami Tameh, M. Nejati et al., “The protective effect of bone marrow mesenchymal stem cells in a rat model of ischemic stroke via reducing the C-Jun N-terminal kinase expression,” Pathology, Research and Practice, vol. 215, no. 9, pp. 152519–152519, 2019.
[15] S. Kiran, “What is the nature of poststroke language recovery and reorganization?,” ISRN Neurology, vol. 2012, 13 pages, 2012.
[16] Y. H. Choi, C. Laaker, M. Hsu, P. Cismaru, M. Sandor, and Z. Fabry, “Molecular mechanisms of neuroimmune crosstalk in the pathogenesis of stroke,” International Journal of Molecular Sciences, vol. 22, no. 17, p. 9486, 2021.
[17] S. R. Martha, L. A. Collier, S. M. Davis et al., “Early acid/base and electrolyte changes in permanent middle cerebral artery occlusion: aged male and female rats,” Journal of Neurosurgery, vol. 98, no. 1, pp. 179–190, 2020.
[18] C. J. Cunningham, E. Redondo-Castro, and S. M. Allan, “The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke,” Journal of Cerebral Blood Flow and Metabolism, vol. 38, no. 8, pp. 1276–1292, 2018.
[19] S. Banerjee, D. A. Williamson, N. Habib, and J. Chataway, “The potential benefit of stem cell therapy after stroke: an update,” Vascular Health and Risk Management, vol. 8, pp. 569–580, 2012.
[20] P. McMeekin, P. White, M. A. James, C. I. Price, D. Flynn, and G. A. Ford, “Estimating the number of UK stroke patients eligible for endovascular thrombectomy,” European Stroke Journal, vol. 2, no. 4, pp. 319–326, 2017.
[21] N. Jean LeBlanc, R. Menet, K. Picard, G. Parent, M. E. Tremblay, and A. Ellali, “Canonical Wnt pathway maintains blood-brain barrier integrity upon ischemic stroke and its activation ameliorates tissue plasminogen activator activity,” Molecular Neurobiology, vol. 56, no. 9, pp. 6521–6538, 2019.
Z. Zhilai, M. Biling, Q. Sujun et al., "S. H. Oh, C. Choi, D. J. Chang et al.,\nH. W. Park, H. E. Moon, H. S. Kim et al.,\nJ. Y. Lim, C. H. Jeong, J. A. Jun et al.,\nC. C. Liang, H. L. Liu, S. D. Chang, S. H. Chen, and T. H. Lee,\nY. Zhu, Y. M. Guan, H. L. Huang, and Q. S. Wang,\n"cord injury, umbilical mesenchymal stem cells in a rat model of spinal\nlimb ischemia in diabetic nude rats, placenta-derived mesenchymal stem cells alleviates critical\nstroke and traumatic brain injury, a review,\n"The protective effect on exper-
test with lack of long-term cell replacement e-
"The immunomodulatory activity of human umbilical cord blood-derived mesenchy-
stem cells in vitro,\n"Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia,\n"Human umbilical cord blood-derived mesenchymal stem cells improve functional recovery through thrombospondin1, pantraxin3, and vascular endothelial growth factor in the ischemic rat brain,\n"Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells: mechanisms of action,\nThe protective effect of human umbilical cord blood CD34+ cells and estradiol against focal cerebral ischemia in female ovariectomized rat: cerebral MR imaging and immunohistochemical study,\n"Transplantation of human placenta-derived mesenchymal stem cells alleviates critical limb ischemia in diabetic nude rats,\n"Preconditioning in low-
ered oxygen enhances the therapeutic potential of human umbilical mesenchymal stem cells in a rat model of spinal cord injury,\n"Challenges and controversies in human umbilical stem cell therapy,\n"Early neuroprotective effect with lack of long-term cell replacement effect on experimental stroke after intra-arterial transplantation of adipose-
derived mesenchymal stromal cells,\nH. S. Peirce, and A. P. Sattah, N. Yang, S. M. Peirce, and\nA. J. Katz, "Human adipose-derived stromal/stem cells demon-
strate short-lived persistence after implantation in both an immunocompetent and an immunocompromised murine model," Stem Cell Research & Therapy, vol. 5, no. 6, p. 142, 2014.
R. Vemuganti, "Stroke: molecular mechanisms and thera-
pies, Neuromolecular Medicine, vol. 21, no. 4, pp. 323–324, 2019.
A. Akella, S. Bhattacharai, and A. Dharap, "Long noncoding RNAs in the pathophysiology of ischemic stroke," Neuromolecular Medicine, vol. 21, no. 4, pp. 474–483, 2019.
K. R. Nalamolu, I. Venkatesh, A. Mohandass et al., "Exosomes secreted by the cocultures of normal and oxygen-glucose-deprived stem cells improve post-stroke outcome," Neuromolecular Medicine, vol. 21, no. 4, pp. 529–539, 2019.
P. J. Darlington, M. N. Boivin, and A. Bar-Or, "Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis," Expert Review of Neurotherapeutics, vol. 11, no. 9, pp. 1295–1303, 2011.
H. Kamel and C. Iadecola, "Brain-immune interactions and ischemic stroke: clinical implications," Archives of Neurology, vol. 69, no. 5, pp. 576–581, 2012.
S. Asgharzade, A. Talaei, T. Farkhondeh, and F. Forouzanfar, "Combining growth factor and stem cell therapy for stroke rehabilitation, a review," Current Drug Targets, vol. 21, no. 8, pp. 781–791, 2020.
P. Connick, M. Kolappan, R. Patani et al., "The mesenchymal stem cells in multiple sclerosis (MSCiMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments," Trials, vol. 12, no. 1, p. 62, 2011.
S. Hombach-Klonisch, S. Panigrahi, I. Rashedi et al., "Adult stem cells and their trans-differentiation potential-perspectives and therapeutic applications," Journal of Molecular Medicine (Berlin, Germany), vol. 86, no. 12, pp. 1301–1314, 2008.
Y. Li and M. Chopp, "Marrow stromal cell transplantation in stroke and traumatic brain injury," Neuroscience Letters, vol. 456, no. 3, pp. 120–123, 2009.
L. Hénaut, M. Grissi, F. Brazier et al., "Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease," Scientific Reports, vol. 9, no. 1, p. 6432, 2019.
E. Tanaka, Y. Ogawa, T. Mukai et al., "Dose-dependent effect of intravenous administration of human umbilical cord-derived mesenchymal stem cells in neonatal stroke mice," Frontiers in Neurology, vol. 9, p. 133, 2018.
E. Potier, E. Ferreira, R. Andriamanalijaona et al., "Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression," Bone, vol. 40, no. 4, pp. 1078–1087, 2007.
H. Xu, S. P. Yu, L. L. Fraser et al., "Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis," The Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799–808, 2008.
S. C. Hung, R. R. Pochampally, S. C. Hsu et al., "Short-term exposure of multipotent stromal cells to low oxygen increases
their expression of CX3CR1 and CXCR4 and their engraftment in vivo," PLoS One, vol. 2, no. 5, article e416, 2007.

[51] S. Iihoshi, O. Honmou, K. Houkin, K. Hashi, and J. D. Kocsis, "A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats," Brain Research, vol. 1007, no. 1-2, pp. 1–9, 2004.

[52] L. H. Shen, Y. Li, J. Chen et al., "Intracarotid transplantation of bone marrow stromal cells increases axon–myelin remodeling after stroke," Neuroscience, vol. 137, no. 2, pp. 393–399, 2006.

[53] K. L. Philpott, M. J. McCarthy, A. Klippel, and L. L. Rubin, "Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons," The Journal of Cell Biology, vol. 139, no. 3, pp. 809–815, 1997.

[54] A. Brunet, S. R. Datta, and M. E. Greenberg, "Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway," Current Opinion in Neurobiology, vol. 11, no. 3, pp. 297–305, 2001.

[55] M. Hetman and A. Gozdzi, "Role of extracellular signal regulated kinases 1 and 2 in neuronal survival," European Journal of Biochemistry, vol. 271, no. 11, pp. 2050–2055, 2004.

[56] Q. H. Guan, D. S. Pei, X. M. Liu, X. T. Wang, T. L. Xu, and G. Y. Zhang, "Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis," Brain Research, vol. 1092, no. 1, pp. 36–46, 2006.

[57] Y. Gao, A. P. Signore, W. Yin et al., "Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway," Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 6, pp. 694–712, 2005.

[58] Y. Li, D. He, X. Zhang et al., "Protective effect of celastrol in rat cerebral ischemia model: down-regulating p-JNK, p-c-Jun and NF-xB," Brain Research, vol. 1464, pp. 8–13, 2012.

[59] Y. Liu, H. Wang, Y. Zhu, L. Chen, Y. Qu, and Y. Zhu, "The protective effect of nordihydroguaiaretic acid on cerebral ischemia/reperfusion injury is mediated by the JNK pathway," Brain Research, vol. 1445, pp. 73–81, 2012.

[60] W. Huang, B. Lv, H. Zeng et al., "Paracrine factors secreted by MSCs promote astrocyte survival associated with GFAP downregulation after ischemic stroke via p38 MAPK and JNK," Journal of Cellular Physiology, vol. 230, no. 10, pp. 2461–2475, 2015.

[61] N. B. Iskand, H. S. Lee, S. Landshamer et al., "Bone marrow stromal cells mediate protection through stimulation of PI3-K/Akt and MAPK signaling in neurons," Neurochemistry International, vol. 50, no. 1, pp. 243–250, 2007.

[62] D. C. Hess, E. Howard, C. Cheng, J. Carroll, W. D. Hill, and C. Y. Hsu, "Hypertonic mannitol loading of NF-kappaB transcripts by Nrf2 in human brain microvascular endothelial cells blocks upregulation of ICAM-1," Stroke, vol. 31, no. 5, pp. 1179–1186, 2000.

[63] H. Clevens and R. Nusse, "Wnt/β-catenin signaling and disease," Cell, vol. 149, no. 6, pp. 1192–1205, 2012.

[64] S. Liebner, M. Corada, T. Bangsow et al., "Wnt/beta-catenin signaling controls development of the blood-brain barrier," The Journal of Cell Biology, vol. 183, no. 3, pp. 409–417, 2008.

[65] K. A. Tran, X. Zhang, D. Predescu et al., "Endothelial β-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis," Circulation, vol. 133, no. 2, pp. 177–186, 2016.

[66] S. X. Cai, A. R. Liu, S. Chen et al., "Activated article: Activation of Wnt/β-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice," Stem Cell Research & Therapy, vol. 6, no. 1, p. 65, 2015.

[67] J. Bao, S. Zhou, S. Pan, and Y. Zhang, "Molecular mechanism of ischemic stroke by integrating miRNA and miRNA expression profiles," Clinical Laboratory, vol. 64, no. 4, pp. 559–568, 2018.

[68] S. Dabrowska, A. Andrzejewska, B. Lukomska, and M. Janowski, "Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles," Journal of Neuroinflammation, vol. 16, no. 1, p. 178, 2019.

[69] W. K. Leong, T. L. Henschall, A. Arthur et al., "Human adult dental pulp stem cells enhance poststroke functional recovery through non-neural replacement mechanisms," Stem Cells Translational Medicine, vol. 1, no. 3, pp. 177–187, 2012.

[70] W. Liao, J. Xie, J. Zhong et al., "Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke," Transplantation, vol. 87, no. 3, pp. 350–359, 2009.

[71] T. Yasuhara, N. Matsukawa, K. Hara et al., "Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke animals," Stem Cells and Development, vol. 18, no. 10, pp. 1501–1514, 2009.

[72] S. W. Yoo, D. Y. Chang, H. S. Lee et al., "Immune following suppression mesenchymal stem cell transplantation in the ischemic brain is mediated by TGF-β," Neurobiology of Disease, vol. 58, pp. 249–257, 2013.

[73] L. H. Shen, Y. Li, J. Chen et al., "One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke," Stroke, vol. 38, no. 7, pp. 2150–2156, 2007.

[74] N. Karlupia, N. C. Manley, K. Prasad, R. Schafer, and G. K. Steinberg, "Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model," Stem Cell Research & Therapy, vol. 5, no. 2, p. 45, 2014.

[75] A. G. Ceulemans, T. Zgavc, R. Kooijman, S. Hachimi-Idrissi, S. Sarre, and Y. Michotte, "The dual role of the neuroinflammation-mediating response after ischemic stroke: modulatory effects of hypothalamic genes," Journal of Neuroinflammation, vol. 7, no. 1, p. 74, 2010.

[76] K. Leong, T. L. Henshall, A. Arthur et al., "Oneyear followup after bone marrow stromal cell treatment in middle-aged female rats with stroke," Stroke, vol. 38, no. 7, pp. 2150–2156, 2007.

[77] N. Karlupia, N. C. Manley, K. Prasad, R. Schafer, and G. K. Steinberg, "Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model," Stem Cell Research & Therapy, vol. 5, no. 2, p. 45, 2014.

[78] V. Donega, C. H. Nijboer, G. van Tilborg, R. M. Dijkstra, A. Kavelaar, and C. J. Heijnen, "Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury," Experimental Neurology, vol. 261, pp. 53–64, 2014.

[79] J. J. Quimby, T. L. Webb, E. Randall, A. Marolf, A. Valdes-Martinez, and S. W. Dow, "Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the
treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats,” *Journal of Feline Medicine and Surgery*, vol. 18, no. 2, pp. 165–171, 2016.

[80] A. M. Hoffman and S. W. Dow, “Concise review: stem cell trials using companion animal disease models,” *Stem Cells*, vol. 34, no. 7, pp. 1709–1729, 2016.

[81] A. M. Herrmann, S. Meckel, M. J. Gounis et al., “Large animals in neurointerventional research: a systematic review on models, techniques and their application in endovascular procedures for stroke, aneurysms and vascular malformations,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 39, no. 3, pp. 375–394, 2019.

[82] P. Gervois, E. Wolfs, J. Ratajczak et al., “Stem cell-based therapies for ischemic stroke: preclinical results and the potential of imaging-assisted evaluation of donor cell fate and mechanisms of brain regeneration,” *Medicinal Research Reviews*, vol. 36, no. 6, pp. 1080–1126, 2016.

[83] A. Nagpal, F. C. Choy, S. Howell et al., “Safety and effectiveness of stem cell therapies in early-phase clinical trials in stroke: a systematic review and meta-analysis,” *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 191, 2017.

[84] M. L. Levy, J. R. Crawford, N. Dib, L. Verkh, N. Tankovich, and S. C. Cramer, “Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke,” *Stroke*, vol. 50, no. 10, pp. 2835–2841, 2019.

[85] S. I. Savitz, V. Misra, M. Kasam et al., “Intravenous autologous bone marrow mononuclear cells for ischemic stroke,” *Annals of Neurology*, vol. 70, no. 1, pp. 59–69, 2011.

[86] A. L. Maria Ferri, A. Bersano, D. Lisini, G. Boncoraglio, S. Frigerio, and E. Parati, “Mesenchymal stem cells for ischemic stroke: progress and possibilities,” *Current Medicinal Chemistry*, vol. 23, no. 16, pp. 1598–1608, 2016.

[87] J. Boltze, M. M. Modo, R. W. Mays et al., “Stem cells as an emerging paradigm in stroke 4: advancing and accelerating preclinical research,” *Stroke*, vol. 50, no. 11, pp. 3299–3306, 2019.

[88] L. L. Cui, E. Kerkela, A. Bakreen et al., “The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infarction volume,” *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 11, 2015.

[89] F. D. Ramirez, P. Motazedian, R. G. Jung et al., “Methodological rigor in preclinical cardiovascular studies: targets to enhance reproducibility and promote research translation,” *Circulation Research*, vol. 120, no. 12, pp. 1916–1926, 2017.

[90] L. Li, Q. Jiang, G. Ding et al., “Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 30, no. 3, pp. 653–662, 2010.

[91] M. Janowski, A. Lyczek, C. Engels et al., “Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 33, no. 6, pp. 921–927, 2013.

[92] J. Y. Chua, A. V. Pendharkar, N. Wang et al., “Intra-arterial injection of neural stem cells using a microneedle technique does not cause microembolic strokes,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 31, no. 5, pp. 1263–1271, 2011.

[93] L. L. Cui, D. Golubiczyk, A. M. Tolpanen, J. Boltze, and J. Jolkkoni, “Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy?,” *Annals of Neurology*, vol. 86, no. 1, pp. 5–16, 2019.

[94] D. Kalladka, J. Linden, K. Pollock et al., “Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study,” *Lancet*, vol. 388, no. 10046, pp. 787–796, 2016.

[95] F. J. Ortega, J. Jolkkoni, N. Mahy, and M. J. Rodriguez, “Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 33, no. 3, pp. 356–364, 2013.

[96] G. Pirzad Jahromi, S. Seidi, S. S. Sadr et al., “Therapeutic effects of a combinatorial treatment of simvastatin and bone marrow stromal cells on experimental embolic stroke,” *Basic & Clinical Pharmacology & Toxicology*, vol. 110, no. 6, pp. 487–493, 2012.

[97] D. C. Wagner, M. Boiko, M. Peters et al., “Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke,” *Exp Transl Stroke Med*, vol. 4, no. 1, p. 17, 2012.

[98] L. L. Cui, F. Nitzsche, E. Pryazhnikov et al., “Integrin a4 over-expression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection,” *Stroke*, vol. 48, no. 10, pp. 2895–2900, 2017.

[99] A. O. Dulamea, “The potential use of mesenchymal stem cells in stroke therapy—From bench to bedside,” *Journal of the Neurological Sciences*, vol. 352, no. 1-2, pp. 1–11, 2015.

[100] S. Li, X. Wang, J. Li et al., “Advances in the treatment of ischemic diseases by mesenchymal stem cells,” *Stem Cells International*, vol. 2016, 6061 pages, 2016.

[101] O. Levy, R. Kuai, E. M. J. Siren et al., “Shattering barriers toward clinically meaningful MSC therapies,” *Science Advances*, vol. 6, no. 30, p. eaba6884, 2020.

[102] D. C. Hess, L. R. Wechsler, W. M. Clark et al., “Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial,” *Lancet Neurology*, vol. 16, no. 5, pp. 360–368, 2017.

[103] S. I. Savitz, D. Yavagal, G. Rappard et al., “A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (recover-stroke),” *Circulation*, vol. 139, no. 2, pp. 192–205, 2019.

[104] M. H. Amer, F. Rose, K. M. Shakesheff, M. Modo, and L. J. White, “Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges,” *NPJ Regen Med*, vol. 2, no. 1, p. 23, 2017.

[105] B. A. Aguado, W. Mulyasasmita, J. Su, K. J. Lampe, and S. C. Heilshorn, “Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers,” *Tissue Engineering. Part A*, vol. 18, no. 7-8, pp. 806–815, 2012.

[106] L. R. Nih, S. T. Carmichael, and T. Segura, “Hydrogels for brain repair after stroke: an emerging treatment option,” *Current Opinion in Biotechnology*, vol. 40, pp. 155–163, 2016.

[107] P. Moshayedi, L. R. Nih, I. L. Llorente et al., “Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain,” *Biomaterials*, vol. 105, pp. 145–155, 2016.
[108] E. Bible, F. Dell’Acqua, B. Solanky et al., “Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by 19F- and diffusion-MRI,” *Biomaterials*, vol. 33, no. 10, pp. 2858–2871, 2012.

[109] Y. Li, Y. Dong, Y. Ran et al., “Three-dimensional cultured mesenchymal stem cells enhance repair of ischemic stroke through inhibition of microglia,” *Stem Cell Research & Therapy*, vol. 12, no. 1, p. 358, 2021.

[110] M. R. Wu, C. H. Lee, and J. K. Hsiao, “Bidirectional enhancement of cell proliferation between iron oxide nanoparticle-labeled mesenchymal stem cells and choroid plexus in a cell-based therapy model of ischemic Stroke,” *International Journal of Nanomedicine*, vol. Volume 15, no. 15, pp. 9181–9195, 2020.

[111] J. Oshita, T. Okazaki, T. Mitsuhara, T. Imura, K. Nakagawa, and T. Otsuka, “Early transplantation of human cranial bone-derived mesenchymal stem cells enhances functional recovery in ischemic stroke model rats,” *Neurologia Medico-Chirurgica (Tokyo)*, vol. 60, no. 2, pp. 83–93, 2020.

[112] A. Asgari Taei, S. Nasoohi, G. Hassanzadeh, M. Kadiyar, L. Dargahi, and M. Farahmandfar, “Enhancement of angiogenesis and neurogenesis by intracerebroventricular injection of secretome from human embryonic stem cell-derived mesenchymal stem cells in ischemic stroke model,” *Biomedicine & Pharmacotherapy*, vol. 140, p. 111709, 2021.

[113] S. M. Ahn, Y. R. Kim, Y. I. Shin et al., “Therapeutic potential of a combination of electroacupuncture and TrkB-expressing mesenchymal stem cells for ischemic stroke,” *Molecular Neurobiology*, vol. 56, no. 1, pp. 157–173, 2019.

[114] B. J. Kondori, M. H. Asadi, H. Bahadoran, A. Yari, and J. R. Sarshoori, “Intra-arterial transplantation of neural stem cells improve functional recovery after transient ischemic stroke in adult rats,” *Bratislavské Lekárske Listy*, vol. 121, no. 1, pp. 8–13, 2020.

[115] X. C. Jiang, J. J. Xiang, H. H. Wu et al., “Neural stem cells transfected with reactive oxygen species-responsive polyplexes for effective treatment of ischemic stroke,” *Advanced Materials*, vol. 31, no. 10, article e1807591, 2019.